---
title: "Xtandi (enzalutamide) in castration-resistant prostate cancer: Safety questions"
description: "Safety questions on Xtandi (enzalutamide) in castration-resistant prostate cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: What are the side effects of Xtandi in nonmetastatic CRPC (PROSPER)? What are the side effects of Xtandi in chemotherapy-naive metastatic CRPC (PREVAIL)? What are the side effects of Xtandi after docetaxel in metastatic CRPC (AFFIRM)? Xtandi vs bicalutamide: how did side effects compare in TERRAIN? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xtandi (enzalutamide) in castration-resistant prostate cancer: Safety questions

Manufacturer: Astellas Pharma US, Inc.; Pfizer Inc.  
Prescribing information: [Xtandi](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf)

Safety questions that apply to every indication of Xtandi are on [Xtandi (enzalutamide), all indications: Safety](https://www.evicenter.com/medical-information/xtandi/safety).

## Side effects

<a id="xtandi-nmcrpc-side-effects"></a>

### What are the side effects of Xtandi in nonmetastatic CRPC (PROSPER)?

Applies to: Non-metastatic castration-resistant prostate cancer (PROSPER)

> “PROSPER enrolled 1401 patients with non-metastatic CRPC, of whom 1395 received at least one dose of study drug. 
> Patients were randomized 2:1 and received either XTANDI at a dose of 160 mg once daily (N = 930) or placebo 
> (N = 465). The median duration of treatment at the time of analysis was 18.4 months (range: 0.0 to 42 months) with 
> XTANDI and 11.1 months (range: 0.0 to 43 months) with placebo.”

Source: [XTANDI: Prescribing information, page 8, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=8)

> “Overall, 32 patients (3.4%) receiving XTANDI died from adverse reactions. The reasons for death with ≥ 2 patients 
> included coronary artery disorders (n = 7), sudden death (n = 2), cardiac arrhythmias (n = 2), general physical health 
> deterioration (n = 2), stroke (n = 2), and secondary malignancy (n = 5; one each of acute myeloid leukemia, brain 
> neoplasm, mesothelioma, small cell lung cancer, and malignant neoplasm of unknown primary site). Three patients 
> (0.6%) receiving placebo died from adverse reactions of cardiac arrest (n = 1), left ventricular failure (n = 1), and 
> pancreatic carcinoma (n = 1). Grade 3 or higher adverse reactions were reported among 31% of XTANDI-treated patients 
> and 23% of placebo-treated patients. Discontinuations with an adverse reaction as the primary reason were reported for 
> 9% of XTANDI-treated patients and 6% of placebo-treated patients. Of these, the most common adverse reaction leading 
> to treatment discontinuation was fatigue, which occurred in 1.6% of the XTANDI-treated patients compared to none of 
> the placebo-treated patients. Table 4 shows adverse reactions reported in PROSPER that occurred at a ≥ 2% higher 
> frequency in the XTANDI arm than in the placebo arm.”

Source: [XTANDI: Prescribing information, page 9, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=9)

> “Table 4. Adverse Reactions in PROSPER 
>
> XTANDI 
> (N = 930) 
> Placebo 
> (N = 465) 
> Grade 1-4<sup>1</sup> 
> (%) 
> Grade 3-4 
> (%) 
> Grade 1-4 
> (%) 
> Grade 3-4 
> (%) 
> Metabolism and Nutrition Disorders 
>       Decreased Appetite 
> 10 
> 0.2 
> 3.9 
> 0.2 
> Nervous System Disorders 
>       Dizziness<sup>2</sup> 
> 12 
> 0.5 
> 5 
> 0 
>       Headache 
> 9 
> 0.2 
> 4.5 
> 0 
>       Cognitive and Attention Disorders<sup>3</sup> 
> 4.6 
> 0.1 
> 1.5 
> 0 
> Vascular Disorders 
>       Hot Flush 
> 13 
> 0.1 
> 8 
> 0 
>       Hypertension 
> 12 
> 4.6 
> 5 
> 2.2 
> Gastrointestinal Disorders 
>       Nausea 
> 11 
> 0.3 
> 9 
> 0 
>       Constipation 
> 9 
> 0.2 
> 7 
> 0.4 
> General Disorders and Administration Site Conditions 
>       Asthenic Conditions<sup>4</sup> 
> 40 
> 4 
> 20 
> 0.9 
> Investigations 
>       Weight Decreased 
> 6 
> 0.2 
> 1.5 
> 0 
> Injury, Poisoning and Procedural Complications 
>       Fall 
> 11 
> 1.3 
> 4.1 
> 0.6 
>       Fractures<sup>5</sup> 
> 10 
> 2 
> 4.9 
> 1.7 
> Psychiatric Disorders 
>       Anxiety 
> 2.8 
> 0.2 
> 0.4 
> 0 
> 1. 
> CTCAE v 4. 
> 2. 
> Includes dizziness and vertigo. 
> 3. 
> Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention. 
> 4. 
> Includes asthenia and fatigue. 
> 5. 
> Includes all osseous fractures from all sites.”

Source: [XTANDI: Prescribing information, page 9, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=9)

Note: Each table row lists XTANDI Grade 1-4, XTANDI Grade 3-4, comparator Grade 1-4, and comparator Grade 3-4 percentages, in that order, as in the table header. The comparator is placebo.

<a id="xtandi-prevail-side-effects"></a>

### What are the side effects of Xtandi in chemotherapy-naive metastatic CRPC (PREVAIL)?

Applies to: Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)

> “PREVAIL enrolled 1717 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 
> 1715 received at least one dose of study drug. The median duration of treatment was 17.5 months with XTANDI and 
> 4.6 months with placebo. Grade 3-4 adverse reactions were reported in 44% of XTANDI-treated patients and 37% of 
> placebo-treated patients. Discontinuations due to adverse reactions were reported for 6% of XTANDI-treated patients. 
> The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of 
> patients on each treatment arm. Table 2 includes adverse reactions reported in PREVAIL that occurred at a ≥ 2% higher 
> frequency in the XTANDI arm compared to the placebo arm.”

Source: [XTANDI: Prescribing information, page 6, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=6)

> “Table 2. Adverse Reactions in PREVAIL 
> XTANDI 
> (N = 871) 
> Placebo 
> (N = 844) 
> Grade 1-4<sup>1</sup> 
> (%) 
> Grade 3-4 
> (%) 
> Grade 1-4 
> (%) 
> Grade 3-4 
> (%) 
> General Disorders 
>      Asthenic Conditions<sup>2</sup> 
> 47 
> 3.4 
> 33 
> 2.8 
>      Peripheral Edema 
> 12 
> 0.2 
> 8 
> 0.4 
> Musculoskeletal and Connective Tissue Disorders 
>      Back Pain 
> 29 
> 2 
> 22 
> 3 
>      Arthralgia 
> 21 
> 1.6 
> 16 
> 1.1 
> Gastrointestinal Disorders 
>      Constipation 
> 23 
> 0.7 
> 17 
> 0.4 
>      Diarrhea 
> 17 
> 0.3 
> 14 
> 0.4 
> Vascular Disorders 
>      Hot Flush 
> 18 
> 0.1 
> 8 
> 0 
>      Hypertension 
> 14 
> 7 
> 4.1 
> 2.3 
> Nervous System Disorders 
>      Dizziness<sup>3</sup> 
> 11 
> 0.3 
> 7 
> 0 
>      Headache 
> 11 
> 0.2 
> 7 
> 0.4 
>      Dysgeusia 
> 8 
> 0.1 
> 3.7 
> 0 
>      Mental Impairment Disorders<sup>4</sup> 
> 6 
> 0 
> 1.3 
> 0.1 
>      Restless Legs Syndrome 
> 2.1 
> 0.1 
> 0.4 
> 0 
> Respiratory Disorders 
>      Dyspnea<sup>5</sup> 
> 11 
> 0.6 
> 8 
> 0.6 
> Infections and Infestations 
>      Upper Respiratory Tract Infection<sup>6</sup> 
> 16 
> 0 
> 11 
> 0 
>      Lower Respiratory Tract And Lung Infection<sup>7</sup> 
> 8 
> 1.5 
> 4.7 
> 1.1 
> Psychiatric Disorders 
>      Insomnia 
> 8 
> 0.1 
> 6 
> 0 
> Renal and Urinary Disorders 
>      Hematuria 
> 9 
> 1.3 
> 6 
> 1.3 
> Injury, Poisoning and Procedural Complications 
>      Fall 
> 13 
> 1.6 
> 5 
> 0.7 
>      Non-Pathological Fracture 
> 9 
> 2.1 
> 3 
> 1.1 
> Metabolism and Nutrition Disorders 
>      Decreased Appetite 
> 19 
> 0.3 
> 16 
> 0.7 
> Investigations 
>      Weight Decreased 
> 12 
> 0.8 
> 8 
> 0.2 
> Reproductive System and Breast Disorders 
>      Gynecomastia 
> 3.4 
> 0 
> 1.4 
> 0 
> 1. 
> CTCAE v 4. 
> 2. 
> Includes asthenia and fatigue. 
> 3. 
> Includes dizziness and vertigo. 
> 4. 
> Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention. 
> 5. 
> Includes dyspnea, exertional dyspnea, and dyspnea at rest. 
> 6. 
> Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis. 
> 7. 
> Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.”

Source: [XTANDI: Prescribing information, page 7, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=7)

Note: Each table row lists XTANDI Grade 1-4, XTANDI Grade 3-4, comparator Grade 1-4, and comparator Grade 3-4 percentages, in that order, as in the table header. The comparator is placebo.

<a id="xtandi-affirm-side-effects"></a>

### What are the side effects of Xtandi after docetaxel in metastatic CRPC (AFFIRM)?

Applies to: Metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy (AFFIRM)

> “AFFIRM enrolled 1199 patients with metastatic CRPC who had previously received docetaxel. The median duration of 
> treatment was 8.3 months with XTANDI and 3.0 months with placebo. During the trial, 48% of patients on the XTANDI 
> arm and 46% of patients on the placebo arm received glucocorticoids. 
> Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients. Discontinuations due to 
> adverse reactions were reported for 16% of XTANDI-treated patients. The most common adverse reaction leading to 
> treatment discontinuation was seizure, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of 
> the placebo-treated patients. Table 1 shows adverse reactions reported in AFFIRM that occurred at a ≥ 2% higher 
> frequency in the XTANDI arm compared to the placebo arm.”

Source: [XTANDI: Prescribing information, page 5, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=5)

> “Table 1. Adverse Reactions in AFFIRM 
>
> XTANDI 
> (N = 800) 
> Placebo 
> (N = 399) 
>
> Grade 1-4<sup>1</sup> 
> (%) 
> Grade 3-4 
> (%) 
> Grade 1-4 
> (%) 
> Grade 3-4 
> (%) 
> General Disorders 
>       Asthenic Conditions<sup>2</sup> 
> 51 
> 9 
> 44 
> 9 
>       Peripheral Edema 
> 15 
> 1 
> 13 
> 0.8 
> Musculoskeletal and Connective Tissue Disorders 
>       Back Pain 
> 26 
> 5 
> 24 
> 4 
>       Arthralgia 
> 21 
> 2.5 
> 17 
> 1.8 
>       Musculoskeletal Pain 
> 15 
> 1.3 
> 12 
> 0.3 
>       Muscular Weakness 
> 10 
> 1.5 
> 7 
> 1.8 
>       Musculoskeletal Stiffness 
> 2.6 
> 0.3 
> 0.3 
> 0 
> Gastrointestinal Disorders 
>       Diarrhea 
> 22 
> 1.1 
> 18 
> 0.3 
> Vascular Disorders 
>       Hot Flush 
> 20 
> 0 
> 10 
> 0 
>       Hypertension 
> 6 
> 2.1 
> 2.8 
> 1.3”

Source: [XTANDI: Prescribing information, page 5, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=5)

> “XTANDI 
> (N = 800) 
> Placebo 
> (N = 399) 
>
> Grade 1-4<sup>1</sup> 
> (%) 
> Grade 3-4 
> (%) 
> Grade 1-4 
> (%) 
> Grade 3-4 
> (%) 
> Nervous System Disorders 
>       Headache 
> 12 
> 0.9 
> 5 
> 0 
>       Dizziness<sup>3</sup> 
> 9 
> 0.5 
> 7 
> 0.5 
>       Spinal Cord Compression and Cauda Equina 
> Syndrome 
> 7 
> 7 
> 4.5 
> 3.8 
>       Paresthesia 
> 7 
> 0 
> 4.5 
> 0 
>       Mental Impairment Disorders<sup>4</sup> 
> 4.3 
> 0.3 
> 1.8 
> 0 
>       Hypoesthesia 
> 4 
> 0.3 
> 1.8 
> 0 
> Infections and Infestations 
>       Upper Respiratory Tract Infection<sup>5</sup> 
> 11 
> 0 
> 6 
> 0.3 
>       Lower Respiratory Tract and Lung Infection<sup>6</sup> 
> 8 
> 2.4 
> 4.8 
> 1.3 
> Psychiatric Disorders 
>       Insomnia 
> 9 
> 0 
> 6 
> 0.5 
>       Anxiety 
> 6 
> 0.3 
> 4 
> 0 
> Renal and Urinary Disorders 
>       Hematuria 
> 7 
> 1.8 
> 4.5 
> 1 
>       Pollakiuria 
> 4.8 
> 0 
> 2.5 
> 0 
> Injury, Poisoning and Procedural Complications 
>       Fall 
> 4.6 
> 0.3 
> 1.3 
> 0 
>       Non-pathologic Fractures  
> 4 
> 1.4 
> 0.8 
> 0.3 
> Skin and Subcutaneous Tissue Disorders 
>       Pruritus 
> 3.8 
> 0 
> 1.3 
> 0 
>       Dry Skin 
> 3.5 
> 0 
> 1.3 
> 0 
> Respiratory Disorders 
>       Epistaxis 
> 3.3 
> 0.1 
> 1.3 
> 0.3 
> 1. 
> CTCAE v 4. 
> 2. 
> Includes asthenia and fatigue. 
> 3. 
> Includes dizziness and vertigo. 
> 4. 
> Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention. 
> 5. 
> Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis. 
> 6. 
> Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.”

Source: [XTANDI: Prescribing information, page 6, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=6)

Note: Each table row lists XTANDI Grade 1-4, XTANDI Grade 3-4, comparator Grade 1-4, and comparator Grade 3-4 percentages, in that order, as in the table header. The comparator is placebo. Table 1 continues from page 5 to page 6 of the Prescribing Information, where its header repeats.

<a id="xtandi-terrain-side-effects"></a>

### Xtandi vs bicalutamide: how did side effects compare in TERRAIN?

Applies to: Chemotherapy-naive metastatic castration-resistant prostate cancer, compared with bicalutamide (TERRAIN)

> “TERRAIN enrolled 375 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 372 
> received at least one dose of study drug. The median duration of treatment was 11.6 months with XTANDI and 
> 5.8 months with bicalutamide. Discontinuations with an adverse reaction as the primary reason were reported for 8% of 
> XTANDI-treated patients and 6% of bicalutamide-treated patients. The most common adverse reactions leading to 
> treatment discontinuation were back pain and pathological fracture, which occurred in 3.8% of XTANDI-treated patients 
> for each event and in 2.1% and 1.6% of bicalutamide-treated patients, respectively. Table 3 shows overall and common 
> adverse reactions (≥ 10%) in XTANDI-treated patients.”

Source: [XTANDI: Prescribing information, page 8, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=8)

> “Table 3. Adverse Reactions in TERRAIN 
>
> XTANDI 
> (N = 183) 
> Bicalutamide 
> (N = 189) 
> Grade 1-4<sup>1</sup> 
> (%) 
> Grade 3-4 
> (%) 
> Grade 1-4 
> (%) 
> Grade 3-4 
> (%) 
> Overall 
> 94 
> 39 
> 94 
> 38 
> General Disorders 
>       Asthenic Conditions<sup>2</sup> 
> 32 
> 1.6 
> 23 
> 1.1 
> Musculoskeletal and Connective Tissue Disorders 
>       Back Pain 
> 19 
> 2.7 
> 18 
> 1.6 
>       Musculoskeletal Pain<sup>3</sup> 
> 16 
> 1.1 
> 14 
> 0.5 
> Vascular Disorders 
>       Hot Flush 
> 15 
> 0 
> 11 
> 0 
>       Hypertension 
> 14 
> 7 
> 7 
> 4.2 
> Gastrointestinal Disorders 
>       Nausea 
> 14 
> 0 
> 18 
> 0 
>       Constipation 
> 13 
> 1.1 
> 13 
> 0.5 
>       Diarrhea 
> 12 
> 0 
> 9 
> 1.1 
> Infections and Infestations 
>       Upper Respiratory Tract Infection<sup>4</sup> 
> 12 
> 0 
> 6 
> 0.5 
> Investigations 
>       Weight Loss 
> 11 
> 0.5 
> 8 
> 0.5 
> 1. 
> CTCAE v 4. 
> 2. 
> Including asthenia and fatigue. 
> 3. 
> Including musculoskeletal pain and pain in extremity. 
> 4. 
> Including nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.”

Source: [XTANDI: Prescribing information, page 8, captured 2026-11-13](https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf#page=8)

Note: Each table row lists XTANDI Grade 1-4, XTANDI Grade 3-4, comparator Grade 1-4, and comparator Grade 3-4 percentages, in that order, as in the table header. The comparator is bicalutamide.

## Related pages
- [Medical information: Xtandi (enzalutamide): Castration-resistant prostate cancer](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer)
- [Indication](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/clinical-trials)
- [Dosing and administration](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/xtandi--castration-resistant-prostate-cancer/guidelines)
